| Autor: |
Jiang JJ; Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China., Jing YY; Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China., Li YY; Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China., Yang YN; Guang'anmen Hospital, China Academy of Chinese Medical Sciences Beijing 100053, China., Liao X; Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China., Xie YM; Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China. |
| Jazyk: |
čínština |
| Zdroj: |
Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica [Zhongguo Zhong Yao Za Zhi] 2024 Feb; Vol. 49 (4), pp. 1102-1112. |
| DOI: |
10.19540/j.cnki.cjcmm.20231108.501 |
| Abstrakt: |
This study systematically combed the randomized controlled trial(RCT) of Chinese patent medicines in treatment of type 2 diabetes mellitus(T2DM) in recent five years by using the method of evidence map. It understood the distribution and quality of evidence in this field and found the existing Chinese patent medicines in treatment of T2DM and the problems in its research. The study collected the commonly used Chinese patent medicines for the treatment of T2DM from three drug catalogs, retrieved Chinese and English databases to obtain RCT literature related to Chinese patent medicines in recent five years, and extracted information such as sample size, study drug, combination medication, course of treatment, and outcome indicators from the literature. It also conducted quality evaluation based on the Cochrane collaborative network bias risk assessment tool and used charts to display the analysis results. A total of 19 kinds of Chinese patent medicines are collected, of which 13 kinds of Chinese patent medicines are mentioned in 131 articles related to RCT. The literature concerning Shenqi Jiangtang Capsules/Granules, Jinlida Granules, and Xiaoke Pills accounts for a large proportion. Outcome indicators include blood glucose, blood lipids, pancreatic islet cell function, and clinical symptoms. In terms of literature quality, 75 articles have correct random methods, and 1 article performs allocation hiding and blind methods. Therefore, the clinical orientation of Chinese patent medicines for the treatment of T2DM is broad, failing to reflect their own characteristics and lacking safety information. Insufficient attention has been paid to TCM syndrome scores, quality of life, and blood lipid outcome indicators that reflect the characteristics of traditional Chinese medicine(TCM). The number of studies on the treatment of T2DM by Chinese patent medicines varies greatly among varieties, and the quality of the studies is low. It is suggested that the holders of the marketing license of T2DM Chinese patent medicines should carry out a post-marketing re-evaluation of the varieties of traditional Chinese patent medicines for treating T2DM according to the relevant requirements of the State Food and Drug Administration, standardize the clinical positioning, and revise and improve the safety information in the instructions. It is recommended that researchers construct a core indicator dataset for Chinese patent medicine treatment of T2DM, improve the efficacy evaluation system, and develop an experimental plan based on CONSORT before conducting RCT. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
